SPRO— AI Stock Forecast & Price Targets
Published 7/28/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live SPRO price forecast →
SPRO remains a high-risk binary play where value hinges on de-risking SP001/IBI355 and monetizing Utebzi royalties against structural revenue collapse. Recent catalysts (KKR $105M financing, Innovent $1.1B deal) have been systematically distributed into, driving the stock to a 52-week low of $1.18 with RSI at 20.7 and price 49% below its 200-SMA. The chart shows broken support at $1.40/$1.27 and a forecast band suggesting limited upside without earnings catalysts.
Price is below $1.20 support; wait for breakout above $1.27 to validate regime shift. If price holds $1.18, consider small accumulation at $1.15-$1.18 with stop-loss at $1.08. Invalidation: close below $1.08 opens vacuum toward $0.80.
Focus on Aug 11 earnings for cash burn run-rate and milestone outflow disclosure. Base target of $1.20 is achievable if Utebzi royalties monetize by Q4'26, but bull target ($1.75) remains distant without SP001 Phase 2 success. Catalyst: positive CD40L safety data or Innovent upfront payments.
Terminal value depends on SP001/IBI355 de-risking and Utebzi royalty monetization by 2028. Structural risk is the timeline for milestone outflows; if Innovent upfronts hit before Utebzi royalties scale, equity dilution will accelerate. Long-term play requires Phase 2 success in IgG4-RD (targeted Q2'27) to unlock $1.1B milestones.
Revenue collapsed 95% Q/Q to $258K in Q1'26, confirming no recurring business. Operating margins are negative (-29.2%) with gross margins at 54.6%, but cash flow is strong ($13.2M FCF) and balance sheet robust ($56.1M cash, current ratio 10.5). The $105M non-dilutive KKR royalty financing monetizes Utebzi royalties, extending runway to 2028, but the company has no revenue beyond milestones. Forward P/E is negative (-1.06) and trailing P/E at 4.37, reflecting extreme valuation risk with no earnings growth trajectory.
The chart shows a broken downtrend with support at $1.40/$1.27 now invalidating as price trades below $1.18. The forecast band (yellow dashed line) suggests limited upside to $1.56 in the near term, but RSI at 20.7 indicates oversold conditions without momentum. SMA20 (-34.4%) and SMA50 (-48.6%) are both below price, confirming a downtrend. The model's directional accuracy is only 56% for 1d horizon vs naive baseline (96%), indicating unreliable short-term forecasting.
Key news includes the $105M non-dilutive royalty financing with KKR and Innovent's $1.1B license deal for SP001/IBI355, but these have been sold into rather than bought. The recent price action shows a 24.8% drop from $1.57 to $1.18 despite positive catalysts, confirming distribution pressure. The tape regime treats every positive headline as a sell signal, with short interest rising (from 4.3% to 6.7%) and retail sentiment overwhelmingly bullish but irrelevant in this micro-cap context.
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord